Change theme to redChange theme to blueChange theme to greenChoose your color
Last Modified Date: 17 Jan 2013
  • |
  • Printer Friendly
  • |
  • Download Adobe Reader
  • |
  • Small Font
  • Medium Font
  • Large Font
Marketing Materials
 
 
Home
Technologies Available for Licensing

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USAMRMCORTA@amedd.army.mil


NOVEL METHOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

A method for the treatment of systemic lupus erythematosus (SLE) by administering antisense cAMP response element modulator (antisense CREM) to patients with systemic lupus erythematosus. The antisense CREM increases the production Interleukin-2 (IL-2) which is decreased in SLE patients. Additionally, this invention relates to taking freshly isolated SLE T cells and transfecting them with TCR .zeta. chain construct in a eukaryotic expression vector, at high efficiency by a recently developed nucleoporation technique for the restoration of TCR/CD3-mediated signaling in the .zeta. chain transfected cells. Reconstitution of deficient TCR .zeta. chain can reverse the TCR/CD3-mediated signaling abnormalities as well as the defective IL-2 production in T cells of SLE patients.

Number:2004-0197316

Application:10/772,704

Date:2004-10-07

Type: Pending

Category: Treatment

More Detail:Visit USPTO.GOVExternal link

For Licensing Opportunities, please contact the ORTA at USAMRMCORTA@amedd.army.mil
 
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRMC Public Affairs Office at:
usamrmcwebmaster@amedd.army.mil or by telephone at (301)619-2736